CurrentRheuma
Get Weekly

Rheumatology journalCurrentRheuma coverage

Annals of the Rheumatic Diseases

What CurrentRheuma has captured from this journal. The coverage figures describe CurrentRheuma's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentRheuma holds 596 Briefs from Annals of the Rheumatic Diseases, most often mechanistic studies and cohort studies.

Recent
32 Briefs
past 90 days
Archive
596 Briefs
research published from January 2023 to today
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 596 Briefs CurrentRheuma has covered from Ann Rheum Dis, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from Annals of the Rheumatic Diseases

All coverage, newest first

  1. Ann Rheum Dis

    ERN-RITA/PReS recommendations for the diagnosis, classification, monitoring, and treatment of childhood idiopathic (primary) angiitis of the central nervous system

    Guideline or statementPediatric

  2. Ann Rheum Dis

    Validation of rheumatoid arthritis low inflammatory activity: a novel clinical target quantifying inflammatory disease activity

    Diagnostic or prognostic studyRA

  3. Ann Rheum Dis

    Global burden and economic cost of musculoskeletal disorders in the working-age population, 1990-2023

    Secondary analysisAcross diseases

  4. Ann Rheum Dis

    The impact of HFE genotypes and iron loading on joint disease: evidence for HFE-associated arthropathy without genetic haemochromatosis

    Research articleGout & crystals

  5. Ann Rheum Dis

    Nicotinamide N-methyltransferase drives fibroblast activation and skin fibrosis in systemic sclerosis

    Research articleSystemic sclerosis

  6. Ann Rheum Dis

    Spatial transcriptomics in immune-mediated necrotising myopathy uncovers a specific necrotic signature related to immune-driven fibrosis

    Research articleMyositis

  7. Ann Rheum Dis

    Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study

    Randomized controlled trialSystemic sclerosis

  8. Ann Rheum Dis

    Real‑world assessment of the effectiveness and response profiles of biologic DMARDs in psoriatic arthritis: findings from an emulated multicentre clinical trial

    Research articleSpondyloarthritis & PsA

  9. Ann Rheum Dis

    International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica

    Guideline or statementVasculitis & PMR

  10. Ann Rheum Dis

    Performance of MRI-based synthetic CT for detecting spinal new bone formation in patients with inflammatory arthritis and healthy controls: a comparison with MRI, CT, and radiography

    Diagnostic or prognostic studySpondyloarthritis & PsA

  11. Ann Rheum Dis

    A CCL20+ macrophage subpopulation is the major producer of TNF in axial spondyloarthritis synovium and is driven by CD40L and a myeloid autocrine circuit

    Research articleSpondyloarthritis & PsA

  12. Ann Rheum Dis

    Kidney spatial multiomics mapping decodes scleroderma renal crisis

    Cohort studySystemic sclerosis

  13. Ann Rheum Dis

    Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment

    Research articleSystemic sclerosis

  14. Ann Rheum Dis

    Type I interferon activation in classical monocytes and GZMK+ CD8+ T cells characterises the ultrasound-negative phase of imminent rheumatoid arthritis

    Research articleRA

  15. Ann Rheum Dis

    DNA methylation signatures distinguish gout from asymptomatic hyperuricaemia and converge with genetic risk at immune-metabolic loci

    Case-control studyGout & crystals

  16. Ann Rheum Dis

    Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial

    Secondary analysisVasculitis & PMR

  17. Ann Rheum Dis

    Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease

    Mechanistic studySystemic sclerosis

  18. Ann Rheum Dis

    Predictive molecular signatures for successful tapering of canakinumab in systemic juvenile idiopathic arthritis

    Secondary analysisPediatric

  19. Ann Rheum Dis

    Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis

    Randomized controlled trialRA

  20. Ann Rheum Dis

    MRI and ultrasound predictors of progression to inflammatory arthritis in anti-CCP–positive individuals with musculoskeletal symptoms without clinical synovitis: a prospective cohort study

    Cohort studyRA

  21. Ann Rheum Dis

    Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design

    Guideline or statementSystemic sclerosis

  22. Ann Rheum Dis

    Sequential disease activity assessment for predicting future treatment trajectories in patients with rheumatoid arthritis treated with JAK inhibitors: a group-based trajectory and landmark analysis

    Cohort studyRA

  23. Ann Rheum Dis

    Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals

    Diagnostic or prognostic studyAcross diseases

  24. Ann Rheum Dis

    Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries

    Cohort studySpondyloarthritis & PsA

  25. Ann Rheum Dis

    Automated detection of active and structural MRI lesions in the sacroiliac joints in axial spondyloarthritis: training and validation across 3 phase III clinical trial datasets

    Diagnostic or prognostic studySpondyloarthritis & PsA

  26. Ann Rheum Dis

    Validation of systemic Juvenile Arthritis Disease Activity Score 10 in adults with Still’s disease

    Diagnostic or prognostic studyAutoinflammatory & rare

  27. Ann Rheum Dis

    Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year

    Cohort studyRA

  28. Ann Rheum Dis

    Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus

    Secondary analysisLupus & APS

  29. Ann Rheum Dis

    Impact of disease activity on bone density, microarchitecture, and biomechanical properties in rheumatoid and psoriatic arthritis over 7 years

    Cohort studyRA

  30. Ann Rheum Dis

    The private truncating Toll-like receptor 7 p.Glu834* variant associates with juvenile-onset systemic lupus erythematosus and pathological cytokine expression in vitro

    Mechanistic studyPediatric

  31. Ann Rheum Dis

    Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial

    Randomized controlled trialLupus & APS

  32. Ann Rheum Dis

    Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases

    Mechanistic studyAcross diseases

  33. Ann Rheum Dis

    Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis—a case series

    Cohort studyRA

  34. Ann Rheum Dis

    Spatially distinct macrophage subsets drive myofibroblast heterogeneity and maladaptive fibrosis in lupus nephritis

    Mechanistic studyLupus & APS

  35. Ann Rheum Dis

    Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies

    Randomized controlled trialSpondyloarthritis & PsA

  36. Ann Rheum Dis

    High-sensitivity flow cytometry in rheumatoid arthritis shows that early B-cell subset depletion is linked to 5-year rituximab response, while failure to deplete B cells occurs early in subsequent poly-refractory disease

    Cohort studyRA

  37. Ann Rheum Dis

    Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases

    Meta-analysisPediatric

  38. Ann Rheum Dis

    Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach

    Guideline or statementPediatric

  39. Ann Rheum Dis

    Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial

    Randomized controlled trialSpondyloarthritis & PsA

  40. Ann Rheum Dis

    Effects of air pollution on disease activity in patients with rheumatoid arthritis

    Cohort studyRA

All 596 Briefs in ExploreShowing the 40 most recently published